In other words, is it feasible that we could have

Quote:

---

In other words, is it feasible that we could have really good evidence in just a couple of days that the respiratory complications have been prevented? Leading to 4 patients going to 20 in a few more days as the results hopefully are good?

---

I think the evidence is being gathered continuously. I am sure Dr. Patterson (for both, business, and humanitarian reasons) is gathering evidence of the efficacy of Leronlimab.

He has the capabilities to do very detailed analysis. Without implying that what is being used is the below copy-and-paste from IncellRX site, they can definitely measure parameters that will demonstrate the anti-inflammatory response(s) of Leronlimab.

Quote:

---

IncellDx technology combines a unique multiplex RNA in situ hybridization method called Simultaneous Ultrasensitive Signal-amplified Hybridization In Situ (SUSHI) with a novel, cell-based instrument capable of quantifying multiple proteins and molecular biomarkers inside intact cells. This allows protein and gene expression to be measured by distinct cell type which aids both diagnosis and disease localization. The company currently has more than 30 issued and pending patents.

---

So, I would argue that they can quantify very rapidly what is happening with the patients and they are being followed very closely.

But, more to the point, I believe he is sharing the information with the physician(s) taking care of the patients so they can know promptly how they are responding to the treatment.

A win-win situation in the scenario that things are working in the right direction as the expanded patient numbers would indicate. As more are treated and results obtained (rapidly) the information will be shared and hopefully more physicians will incorporate Leronlimab in their treatment under IND.